Multiple sclerosis (MS) is an inflammatory, demyelinating disease considered by most who are expert in the field to have an autoimmune origin. However, a small number of investigators have postulated a vascular association since the time of the first histologic description of MS by Charcot [1] . A central vein can be seen by magnetic resonance (MR) venography in MS plaques [2] , and results of other imaging studies have indicated a correlation between the location of MS lesions and venous structures [3, 4] . In 2009, these theories of a vascular association gathered prominence after 2 publications by Professor Paolo Zamboni from Ferrara, Italy [5, 6] . In his publications, Zamboni coined the term chronic cerebrospinal venous insufficiency (CCSVI) to describe a constellation of extracranial venous obstructions that he observed in patients with MS, and the treatment of this disorder has been labelled the ''Liberation Procedure.''
The first article [5] , an unblinded nonrandomized study described 4 patterns of venous abnormalities in 65 of 65 patients with MS and in 0 of 48 patients in a control group, which consisted of healthy subjects and patients with neurologic diseases other than MS. The article reported a 100% sensitivity, specificity, positive predictive value, and negative predictive value. He classified these abnormalities as type A, stenosis of the proximal azygos associated with stenosis of 1 of the 2 internal jugular veins; type B, bilateral stenosis of internal jugular veins and proximal azygos stenosis; type C, bilateral stenosis of the internal jugular veins, with a normal azygos venous system; and type D, various stenoses of the azygos system. Zamboni's hypothesis is that impaired venous drainage from chronic cerebrospinal venous insufficiency leads to iron deposition in interstitial brain tissue, which has a role in the pathogenesis of MS. Increased iron density in MS plaques has been suggested by susceptibility-weighted imaging [7] .
In November 2009, Zamboni published an open-label intervention study of endovascular treatment of CCSVI and reported significant improvement in disease severity outcome measures in the same patient population, particularly the subgroup of patients with a relapsing remitting type of MS [6] . Treatment included both angioplasty and stenting, although the numbers of each and their precise locations were not specified in the publication. The outcomes were reported relative to pretreatment status and in the absence of a control group. The proportion of patients who were relapse free changed from 27% to 50% and those with gadoliniumenhancing lesions on magnetic resonance imaging decreased from 50% to 12%. The Multiple Sclerosis Functional Composite Index at 1 year improved in patients with relapsing remitting MS but not in those with primary or secondary progressive disease. Physical quality of life scale improved in patients with relapsing remitting and primary progressive disease, and a positive trend was seen in those with secondary progressive disease. Mental quality of life scale also improved in patients with relapsing remitting and primary progressive disease but not in secondary progressive MS.
To summarize, an intriguing small single-centre body of work was published that described a possible advance in the management of a serious chronic progressive and disabling disease. Effective treatments exist that prevent disease progression and relapses. However, there are no effective treatments for reversing chronic disability, and only limited treatments for improving common symptoms, such as fatigue and bladder dysfunction. As is typical with a new minimally invasive treatment, the first report was not a randomized or blinded trial. In the normal course of clinical development, the data, hypothesis, and treatment techniques would be discussed, analysed, and modified, and the data confirmed or refuted by further independent studies, optimally controlled, randomized, and multicentre. However, Zamboni's work [5, 6] was widely reported in the Canadian popular press, and, to say the least, considerable interest has been generated within a very electronically connected MS community. Patients demanded and have been frustrated that the Canadian health care system was not able to immediately offer the ''Liberation Procedure'' to them. MS experts nationally and globally have generally discounted Zamboni's work as a scientifically unsound theory, with clinical results not unexpected from the placebo effect commonly seen in unblinded, uncontrolled MS studies. In each province, departments of health and medical licensing boards have determined that there is insufficient evidence on efficacy and safety to allow this procedure as part of routine care for Canadian patients with MS. These events have been a vivid lesson to the medical community about the impacts of social media, electronic communication, and a society increasingly accustomed to instant access to everything. The Canada has one of the highest per capita incidences of MS in the world; more than 60,000 Canadians are affected.
MS is a unique disease in the degree to which symptoms can wax and wane. There can be a significant placebo effect in controlled MS trials, for example, ranging from 30%-50% improvement in annualized relapse rates [8] At the time of writing, there are no data on the incidence of stenoses in the jugular veins of the general population or outcomes of endovenous jugular venous interventions of any type, let alone controlled trials in CCSVI.
There is no consensus as to what constitutes a jugular vein stenosis, best modality for diagnosis, how to treat a primary stenosis, how to prevent or treat restenosis, or optimal methods of follow-up. A cash-strapped heavily-controlled public health care system that, by its unique design, has never easily adapted to new minimally invasive therapies increasingly demands a higher burden of proof before incorporating new therapies. Patients who wish to obtain treatments that have not yet been approved frequently do not understand how limited the ability is for physicians to affect change within this system. Every new development, real and rumored, is distributed throughout the world via social networks. Physicians, administrators, and politicians are being asked to respond to new developments, sometimes within hours of their first discussion. MS neurologists are conservative as a group and tend to demand high levels of proof for any therapy. Neurologists are extremely aware of the high incidence of placebo effect in MS trials. There have been prior treatments, for example, hyperbaric oxygen therapy, which initially looked so promising that it warranted publication in the New England Journal of Medicine, but subsequently proved ineffective [9] . Endovascular therapists tend to be ''can do'' personalities and work in a discipline in which such stringent levels of documentation are often not available or even possible. Most endovascular therapies that required a 5-year study would be outdated by the time the study was over.
Radiologists in Canada Are Faced With 3 Distinct Problems

Patients Requesting Investigation for CCSVI
There is considerable debate as to whether CCSVI exists as an entity, let alone whether it affects the pathogenesis of MS. If one examines the jugular veins by using the techniques commonly performed to diagnose venous insufficiency in the lower extremities, then subtle abnormalities will be found in virtually all patients, whether or not they have MS. The significance of these abnormalities are hard to define. Zamboni's ultrasound technique [5, 6] is a nuanced examination, in the our opinion, which requires special instruction and considerable practice, even for those with extensive vascular imaging experience. There is uncertain direction from the various provincial health ministries as to whether investigation for CCSVI is allowed within the public system.
Patients Requesting Treatment for CCSVI
The Canadian Interventional Radiology Association and Canadian Society of Vascular Surgery both consider treatment for CCSVI to be unproven and recommend it only be offered within the context of a clinical trial. To our knowledge, there are no ongoing therapeutic trials in Canada. We strongly recommend that a sham-controlled, randomized, prospective trial of angioplasty be conducted as soon as possible. We recognize and respect the differing opinions among the research community on how much time and funding should be spent addressing the validity of this theory and treatment. The scientific rationale and current level of evidence that surrounds the theory that CCSVI exists and contributes significantly to the pathogenesis and/or symptoms of MS is clearly not complete. In Canada, we are facing an unprecedented number of individuals with MS who are seeking out of country treatment by ''for profit'' centres, many of which use questionable diagnostic, treatment, and follow-up criteria. CCSVI research should include welldesigned trials that address pressing public health concerns, even when there may not yet a robust body of scientific evidence.
Patients Treated for CCSVI out of Country and Requesting Investigation and Care After Returning to Canada
At the time of this writing, there are no standardized protocols for antiplatelet therapy after jugular venous intervention. The most commonly used pharmaceutical regimen after peripheral vascular stent insertion is clopidogrel 325 mg by mouth daily for 1-3 months and acetylsalicylic acid 80 mg by mouth daily for life. We recommend that this or another protocol of choice to local interventionists be distributed to their local MS neurologists. At the time of writing, there are no standardized protocols for follow-up after jugular venous intervention. We believe that the most important issue is that patients continue routine MS care from their neurologist. Defining a program for timing and method of imaging follow-up is more problematic:
I. If the patient has been treated with a stent, then we recommend the following: a. The patient is obligated to provide details about the size, number, and type of stent(s) before any follow-up imaging. b. A radiograph and/or ultrasound are recommended to document the position of the stent(s); there has been at least one incidence of a jugular stent placed for CCSVI that migrated into the heart. c. There are no data on how long a period must pass before a jugular venous stent can be considered stable. The frequency and duration of surveillance is unknown at this time. d. Because of the risk of stent migration into the heart, the patient should be advised by his or her neurologist to seek medical attention for chest pain, palpitations, or neck pain. Neck and chest radiograph should be considered if these occur. e. There are a number of patients for whom an ultrasound has been interpreted as showing ''clot within the stent.'' There is no other area of the body where stents are so close to the skin surface and thus seen in such detail on ultrasound as the jugular vein. One of us (L.M.) has been sent images of 3 patients with this tentative diagnosis; in each case, the findings were clearly of intimal hyperplasia, and no clot was seen. It is not clear at this time if clot formation is a common event. f. It is not clear whether imaging should include assessment for restenosis. At this time, the natural history of intimal hyperplasia (the biologic process of restenosis after endovascular procedures) in jugular venous stents is unknown. When found, there is no proven method for treatment of jugular vein in-stent restenosis. Candidate therapies include insertion of a stent within a stent or a covered stent. These considerably ''up the ante,'' because they may require lifetime clopidogrel therapy and increase the risk of central migration. These risks are difficult to balance against benefit when definitive proof that endovascular treatment of CCSVI alters the clinical course of MS has not yet been achieved. Although abrupt surgical jugular vein ligation has not resulted in untoward morbidity, it is not clear if jugular venous stent occlusion is also innocuous. II. Physicians in Canada are obligated to treat complications regardless of where an original procedure was done. If a stent migrates into the heart, then none of us are confused about our duties to the patient. More problematic is that there has not been consistent direction from Canadian regulatory bodies regarding how to care for patients in the public system who initially perceived benefit after endovascular treatment for CCSVI, then have a return of their symptoms. Symptom recurrence in patients who have had treatment for CCSVI could potentially happen for 2 reasons. One is that the perceived benefit was placebo effect (see above). The second is that there actually was a treatment effect and that the angioplasty or stent has renarrowed (restenosis). Most patients assume the latter. As stated above, there are no data on restenosis after jugular vein interventions, and we certainly do not have data on the best method to treat it.
Summary
We are experiencing a unique medical issue that has been exacerbated by the new reality of near instantaneous sharing of information. MS is a terrible disease, and patients deserve our compassion and understanding when they hear reports of a possible treatment and want to act upon it. Less obvious to many patients is the extremely limited knowledge base about the diagnosis of CCSVI or consequences of endovenous jugular vein interventions and the lack of a robust therapy for jugular vein stenosis. Our obligation to these patients is to ensure they are made aware of these facts, advise that, for the immediate future, any interventions performed should ideally be within properly performed clinical trials and wherever possible advocate for the earliest possible funding of these studies. 
